Jupiter (JUNS) news
Recent news
Jupiter Neurosciences announces pricing of $2.0 million registered direct offering
AInvest Wire · Aug 21, 2026Jupiter Neurosciences - approves 1-for-75 reverse stock split of common stock
AInvest Wire · Aug 5, 2026Jupiter Neurosciences - royalty of 3% of net sales after third commercialization milestone
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has outlined a potential licensing agreement with PharmAla Biotech Holdings Inc. for the U.S. rights to ALA-002, a proprietary, next-generation MDMA formulation. Under the terms of the non-binding Term Sheet, the company would receive a 3% royalty on U.S.…
AInvest Wire · Jul 21, 2026Pharmala Biotech - to manufacture GMP-grade ALA-002 for Jupiter under separate supply agreement
AInvest Wire · Jul 21, 2026Jupiter Neurosciences strengthens board with appointment of Dr. Tomas J. Philipson
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors, effective June 26, 2026 . Philipson, a health care economist, will serve on the Audit and Compensation Committees . His extensive background includes roles such as acting…
AInvest Wire · Jul 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.